Roferon is indicated for Follicular Non-Hodgkin Lymphoma
Follicular Lymphoma (FL)
1. Approved Labelling
Roferon is indicated for Follicular Non-Hodgkin Lymphoma.
2. Treatment Regimen
Roferon-A should be administered concomitantly to a conventional chemotherapy regimen (such as the combination of cyclophosphamide, prednisone, vincristine and doxorubicin) according to a schedule such as 6 million IU/m2 given subcutaneously from day 22 to day 26 of each 28-day cycle.
Please see section 4.4 of the SmPC.
All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.